Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS.
EMTRIVA vs LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by competing with natural substrates and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing conformational disruption. Zidovudine is an NRTI that inhibits viral reverse transcriptase after intracellular phosphorylation to its active triphosphate form.
Emtricitabine 200 mg orally once daily.
One tablet (150 mg lamivudine/200 mg nevirapine/300 mg zidovudine) orally twice daily.
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Lamivudine: 5-7h (adults), prolonged in renal impairment. Nevirapine: 25-30h (single dose), 40-45h (multiple doses, autoinduction). Zidovudine: 0.5-3h (terminal), prolonged in hepatic impairment.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Lamivudine: ~70% renal (glomerular filtration and tubular secretion, unchanged). Nevirapine: ~80% biliary/fecal (metabolites), ~10% renal (unchanged). Zidovudine: ~75% renal (metabolism to glucuronide, tubular secretion).
Category C
Category A/B
Antiretroviral, NRTI
NRTI